DRX-065 is a stabilized and deuterated R-enantiomer of pioglitazone. DRX-065 has pharmacological properties desirable for the treatment of NASH (mitochondrial function modulation,non-steroidal anti-inflammatory effects,and glucose lowering effects)without the undesired PPARγ-related weight gain side effect.